Patents by Inventor Jeffrey Tyner

Jeffrey Tyner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ASSAYS AND METHODS FOR SELECTING A TREATMENT REGIMEN FOR A SUBJECT WITH LEUKEMIA
    Publication number: 20230279503
    Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.
    Type: Application
    Filed: May 12, 2023
    Publication date: September 7, 2023
    Inventors: Max GORDON, Paul TARDI, Jeffrey TYNER, Lawrence MAYER
  • Assays and methods for selecting a treatment regimen for a subject with leukemia
    Patent number: 11746386
    Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: September 5, 2023
    Assignees: CELATOR PHARMACEUTICALS, INC., OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Max Gordon, Paul Tardi, Jeffrey Tyner, Lawrence Mayer
  • COMBINATIONS OF AGENTS TO TREAT HEMATOLOGICAL MALIGNANCIES
    Publication number: 20220280519
    Abstract: Methods of treating acute myeloid leukemia, chronic lymphocytic leukemia and myeloproliferative neoplasms that involve the administration of combinations of small molecule compounds are disclosed.
    Type: Application
    Filed: April 15, 2022
    Publication date: September 8, 2022
    Applicant: Oregon Health & Science University
    Inventors: Jeffrey Tyner, Stephen Kurtz, Brian Druker, Elie Traer, Christopher Eide, Motomi Mori, Andrew Kaempf
  • METHODS OF TREATING VENETOCLAX-RESISTANT ACUTE MYELOID LEUKEMIA
    Publication number: 20220133715
    Abstract: The present invention concerns novel methods of treatment for venetoclax-resistant acute myeloid leukemia, particularly in subjects with a low expression of TP53 protein or expression of TP53 protein associated with a mutation of the TP53 gene, the methods comprising administering to the subject in need thereof a therapeutically effective amount of a NTRK/ALK/ROS1 inhibitor, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 26, 2020
    Publication date: May 5, 2022
    Applicant: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: JEFFREY TYNER, TAMILLA NECHIPORUK, STEPHEN KURTZ, SHANNON MCWEENY
  • ASSAYS AND METHODS FOR SELECTING A TREATMENT REGIMEN FOR A SUBJECT WITH LEUKEMIA
    Publication number: 20210246512
    Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.
    Type: Application
    Filed: February 11, 2021
    Publication date: August 12, 2021
    Applicants: Celator Pharmaceuticals, Inc., Oregon Health & Science University
    Inventors: Max GORDON, Paul TARDI, Jeffrey TYNER, Lawrence MAYER
  • Assays and methods for selecting a treatment regimen for a subject with leukemia
    Patent number: 10927418
    Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: February 23, 2021
    Assignees: Celator Pharmaceuticals, Inc., Oreoon Health & Science University
    Inventors: Max Gordon, Paul Tardi, Jeffrey Tyner, Lawrence Mayer
  • COMBINATIONS OF AGENTS TO TREAT HEMATOLOGICAL MALIGNANCIES
    Publication number: 20200054639
    Abstract: Methods of treating acute myeloid leukemia, chronic lymphocytic leukemia and myeloproliferative neoplasms that involve the administration of combinations of small molecule compounds are disclosed.
    Type: Application
    Filed: October 31, 2017
    Publication date: February 20, 2020
    Applicant: Oregon Health & Science University
    Inventors: Jeffrey Tyner, Stephen Kurtz, Brian Druker, Elie Traer, Christopher Eide, Motomi Mori, Andrew Kaempf
  • ASSAYS AND METHODS FOR SELECTING A TREATMENT REGIMEN FOR A SUBJECT WITH LEUKEMIA
    Publication number: 20180327854
    Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.
    Type: Application
    Filed: November 10, 2016
    Publication date: November 15, 2018
    Applicants: Celator Pharmaceuticals Inc., OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Max GORDON, Paul TARDI, Jeffrey TYNER, Lawrence MAYER
  • METHODS OF DIAGNOSING AND TREATING aCML and CNL
    Publication number: 20170044625
    Abstract: Disclosed herein are methods and kits used in treating a cancer characterized by aberrant activity of CSF3R. These methods involve detecting a mutation in exon 14 of CSF3R such as a mutation of T615 or T618 and treating the subject with a JAK inhibitor and/or detecting a mutation in exon 17 of CSF3R and treating with dasatinib or tyrosine kinase inhibitor with one or more targets in common with dasatinib.
    Type: Application
    Filed: October 27, 2016
    Publication date: February 16, 2017
    Inventors: Jeffrey Tyner, Julia Maxson, Brian Druker
  • METHODS OF DIAGNOSING AND TREATING aCML and CNL
    Publication number: 20140303181
    Abstract: Disclosed herein are methods and kits used in treating a cancer characterized by aberrant activity of CSF3R. These methods involve detecting a mutation in exon 14 of CSF3R such as a mutation of T615 or T618 and treating the subject with a JAK inhibitor and/or detecting a mutation in exon 17 of CSF3R and treating with dasatinib or tyrosine kinase inhibitor with one or more targets in common with dasatinib.
    Type: Application
    Filed: April 4, 2014
    Publication date: October 9, 2014
    Inventors: Jeffrey Tyner, Julia Maxson, Brian Druker
  • METHODS OF DIAGNOSING AND TREATING aCML and CNL
    Publication number: 20140303180
    Abstract: Disclosed herein are methods and kits used in treating a cancer characterized by aberrant activity of CSF3R. These methods involve detecting a mutation in exon 14 of CSF3R such as a mutation of T615 or T618 and treating the subject with a JAK inhibitor and/or detecting a mutation in exon 17 of CSF3R and treating with dasatinib or tyrosine kinase inhibitor with one or more targets in common with dasatinib.
    Type: Application
    Filed: April 4, 2014
    Publication date: October 9, 2014
    Inventors: Jeffrey Tyner, Julia Maxson, Brian Druker